newsfilter
← Latest News
GlobeNewswire·

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA,